CLINICAL TRIALS PROFILE FOR DYANAVEL XR 5
✉ Email this page to a colleague
All Clinical Trials for DYANAVEL XR 5
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03088267 ↗ | Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study | Completed | Tris Pharma, Inc. | Phase 3 | 2017-02-11 | This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years. |
NCT03610464 ↗ | Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years | Completed | Tris Pharma, Inc. | Phase 4 | 2018-05-07 | The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine extended release oral suspension. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DYANAVEL XR 5
Condition Name
Clinical Trial Locations for DYANAVEL XR 5
Trials by Country
Clinical Trial Progress for DYANAVEL XR 5
Clinical Trial Phase
Clinical Trial Sponsors for DYANAVEL XR 5
Sponsor Name